In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

GSK and Myogen sign two PAH agreements

Executive Summary

Myogen (develops small molecules for cardiovascular diseases) licensed GlaxoSmithKline ex-US commercialization rights to the Phase III pulmonary arterial hypertension (PAH) compound ambrisentan. Concurrently, GSK has licensed Myogen US marketing and distribution rights to sell its PAH drug Flolan (epoprostenol) for three years.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register